Washington, D.C. Partner David Rosen was quoted in an Inside Health Reform article on July 17, 2013 titled, “FDA Legal Action Holds N.J. Compounder to Manufacturing Standards.” The article discusses a recent consent decree of permanent injunction against a drug compounder that FDA previously flagged mandates the pharmacy follow drug manufacturer standards. Mr. Rosen was quoted saying, “They’re holding them to drug manufacturer-style GMPs.” He also noted that drug companies involved in consent decrees sometimes enter a plan to rehab some of their products, whether it be active pharmaceutical ingredients or ingredients in process, but this must be approved by FDA and there is often a bond to ensure it is carried out.
People
Related News
20 December 2024
In the News
Foley Attorneys Explore Alice Patent Eligibility Analysis Divergence
Foley & Lardner LLP attorneys Jack Carroll, Chethan Srinivasa, and Kevin Malaney authored the IP Litigator article, "Alice Patent Eligibility Analysis Divergence Before USPTO and District Court."
19 December 2024
In the News
Jason Mehta Shares Perspective on Biggest Government Contracts Cases of 2024
Foley & Lardner LLP partner Jason Mehta commented on the legal battle over the constitutionality of the False Claims Act's qui tam provision in the Law360 article, "Top Gov't Contracts Cases Of 2024."
19 December 2024
In the News
Key Rulings On Sentencing Guidelines After Loper Bright
The U.S. Sentencing Guidelines are instrumental in criminal sentencing, as they provide courts with advisory ranges for imposing sentences.